FDA advisory panel recommends Grail blood test despite trial results
An FDA advisory panel recommended approval for Grail's multicancer screening test earlier this year even after a randomized trial failed to meet its primary endpoint.
Trial outcomes and regulatory recommendation
The company conducted a randomized study involving 140,000 participants to evaluate the blood test. The trial used a surrogate endpoint that the panel did not meet according to available reports. Despite this failure, the advisory group suggested moving forward with approval for the product.
Legislative coverage and financial implications
A new law passed earlier this year allows Medicare to cover the screening test. This legislation means taxpayers may pay for the procedure if the company receives approval. Critics argue that the test showed little promise in early studies before this recommendation.
Corporate history and legal challenges
Grail has faced lawsuits from its own investors in 2024 and 2026 regarding the product claims. The company also worked with England's National Health Service on a large public trial. Former Prime Minister David Cameron served as a paid adviser for that specific project.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.